PFIZER, INC.

(PFE)
  Report
Delayed Nyse  -  05/27 04:03:15 pm EDT
53.91 USD   -0.15%
05/27PFIZER INC : Berenberg sticks Neutral
MD
05/27ViiV Healthcare commits to grant voluntary licence for patents relating to cabotegravir long-acting for PrEP to Medicines Patent Pool
AQ
05/274D pharma Plans Phase 2 Trial for Metastatic Urothelial Carcinoma Maintenance Therapy
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Health Canada To OK Pfizer's COVID-19 Antiviral Pill

01/17/2022 | 10:21am EDT


© MT Newswires 2022
All news about PFIZER, INC.
05/27PFIZER INC : Berenberg sticks Neutral
MD
05/27ViiV Healthcare commits to grant voluntary licence for patents relating to cabote..
AQ
05/274D pharma Plans Phase 2 Trial for Metastatic Urothelial Carcinoma Maintenance Therapy
MT
05/26ZOOM VIDEO COMMUNICATIONS, INC. : An attempt to reconnect
05/26Pfizer Receives US FDA Fast Track Designation for Ervogastat/Clesacostat Combination to..
MT
05/26Malawi Among 5 First Five African Countries to Benefit From Pfizer Health Accord
AQ
05/26Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for th..
BU
05/26Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for th..
CI
05/26Pfizer Launches 'An Accord for a Healthier World' to Improve Health Equity for 1.2 Bill..
AQ
05/26Supreme Court says watchdogs should pay fees
AQ
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 104 B - -
Net income 2022 35 662 M - -
Net cash 2022 15 298 M - -
P/E ratio 2022 8,99x
Yield 2022 3,01%
Capitalization 302 B 302 B -
EV / Sales 2022 2,76x
EV / Sales 2023 3,56x
Nbr of Employees 79 000
Free-Float 58,2%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 53,91 $
Average target price 57,50 $
Spread / Average Target 6,67%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-8.70%302 483
JOHNSON & JOHNSON5.86%476 521
ELI LILLY AND COMPANY17.11%291 184
ROCHE HOLDING AG-13.00%281 098
ABBVIE INC.10.78%265 067
NOVO NORDISK A/S0.49%241 552